Off-label use of antimalarials (chloroquine and hydroxychloroquine) in patients with COVID-9 infections requires close monitoring because of the risks of potentially fatal arrhythmias, advises the US FDA in a Drug Safety Communication.

Serious and potentially life-threatening long QT syndrome, ventricular fibrillation and ventricular tachycardia have been reported during off-label use of chloroquine and hydroxychloroquine in patients with COVID-19.

\"While clinical trials are ongoing to determine the safety and effectiveness of these drugs for COVID-19, there are known side effects of these medications that should be considered. We encourage health care professionals making individual patient decisions closely screen and monitor those patients to help mitigate these risks. The FDA will continue to monitor and investigate these potential risks and will communicate publicly when more information is available,\" said FDA Commissioner Dr Stephen Hahn.

The FDA has reviewed and continues to review cases of serious heart-related adverse events (AEs) and death in patients with COVID-19 receiving hydroxychloroquine or chloroquine alone or in combination with azithromycin or other medicines, reported in the FDA Adverse Event Reporting System database, the American Association of Poison Control Centers National Poison Data System, and published medical literature. Patients with other comorbidities including heart disease and kidney disorders are likely to be at increased risk of these AEs, the FDA advises.
